July Emerging Medical Technologies Report

Published January 2012 | 15 Pages | 30 Exhibits |


Order individually or subscribe and get a complete intel platform.


This report includes details on 30 emerging medical technology companies that have been identified by LSI's in-house research team in July 2012.

All companies include technology, market(s), key executive, and contact information.

Coverage includes innovations in a broad spectrum of medical technology areas including:
- Aesthetics/Dermatology Companies
- Biomaterials Companies
- Biotechnology/Cell Therapy Companies
- Cardiovascular Companies
- Dental Companies
- Diagnostics Companies
- Drug Delivery Companies
- Endocrine Companies
- Gastroenterology Companies
- Gynecology/Women's Health Companies
- Imaging Companies
- Neurology Companies
- Oncology Companies
- Ophthalmology Companies
- Orthopedics Companies
- Pain Management Companies
- Patient Management/Monitoring Companies
- Pharmaceutical Companies
- Respiratory Companies
- Spine Companies
- Surgery Companies
- Urology Companies
- Vascular Companies
- Wound Management Companies

This report is included in LSI's Emerging Medical Technologies® Database.

Table of Contents


•Fatty acid synthase (FASN) inhibitors with pharmaceutical properties that overcome the shortcomings of earlier generations of inhibitors, for the treatment of chronic hepatitis C virus (HCV) and pancreatic, prostatic, breast, and colorectal tumors
•A custom fit, rehabilitative body suit that offers instantaneous back pain relief, trains and conditions the body to prevent or rehabilitate from back injuries, and increases the overall long-term health of the spine
•Biomaterial and regenerative medicine products for ophthalmological applications: ologen(R) Collagen Matrix, BioCornea, and Biolens
•First-in-class, small molecule compounds that successfully manage and treat chronic pain, by inhibiting P2X3 receptors
•Biomaterials for post-surgical adhesion prevention, scar prevention, wound care, and tissue reconstruction
•Micro-catheter platform that uses a proprietary microfluidic design for the delivery of drug/active molecules directly to the central nervous system for the treatment of difficult/chronic neurological conditions
•Protein therapeutics with extremely high target binding specificity for the treatment of cancer and immune-mediated diseases
•An antibody that blocks the calcitonin gene-related peptide (CGRP) pathway to prevent migraine headaches
•Drugs for the treatment of depression, anxiety, epilepsy, pain, glaucoma, spasticity, and a variety of other CNS-related conditions
•Nanopharmaceuticals optimized to make drugs more effective and with fewer side effects
•Ocular microinjection platform for non-surgical, targeted delivery of drugs and proteins into the suprachoroidal space
•Biology and chemistry platforms for the development of small molecule drugs to stop Alzheimer's disease and other CNS-related conditions
•New generation of fully recombinant, protease-activated monoclonal antibodies that can achieve unprecedented levels of tissue-specific targeting
•A recombinant protein to treat X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disorder that can be life-threatening
•Minimally invasive, image-guided breast biopsy and tissue removal technologies
•Products that support transcatheter interventions for the heart
•Non-invasive series of genetic tests, designed to offer valuable insights into the biology of patients with mood disorders and to support the development of personalized medicine
•New avenue of nucleotide therapeutic drug discovery via modulation of cellular miRNA to treat a wide range of diseases, including cancer, fibrosis, inflammation, and infectious and degenerative diseases
•Diagnostic tests for the early identification of newborns suffering from critical oxygen supply deficit during birth (Asphyxia), a major cause for brain injury, often followed by life-long disability
•A device that enables surgeons to check for remaining cancer cells at the tumor site, immediately following surgical removal of the tumor
•The first vaccine to demonstrate efficacy in reducing the mortality of otherwise highly lethal bloodstream infections due to either Candida or S. aureus (including MRSA)
•Drugs to improve health for patients by modulating disease-associated long non-coding RNA (lncRNA), thereby restoring normal expression of individual targeted genes
•Neuromonitoring devices to prevent nerve damage in all types of surgical procedures
•Novel technology for the treatment of acne
•Fully synthetic and targeted vaccines that induce an antigen-specific immune activation or an antigen-specific immune tolerance for therapeutic and prophylactic applications
•Technology that will allow hospitals to consolidate the multiple types of infusion pumps used throughout their organization into a single type of device
•A laser procedure that removes the brown pigment (melanin) from the top layer of the iris, in order to change human eye color (to blue) permanently
•Decision support software, integrated with vital sign monitoring equipment in hospital ICUs/EDs, to provide novel insights into a patient's current status and future trajectory
•Revolutionary topical antifungal with: exceptional potency, the ability to penetrate the nail, a dual mode of action, and exemplary safety profile
•Unique diagnostic and monitoring technologies: 1-"Smart Optic Capillaroscope" for non-invasive diagnostics of early disorders in the smallest vessels-capillaries; 2-"Hemodynamic Lab" for simultaneous diagnostics of the whole vascular system; and 3-"Meteolaboratory with Feedback Effect" for controlling influence of meteorological factors on the human organism

Accelerate your business

We’re here to help you make smarter decisions and form stronger partnerships through curated events, independent market intelligence products and services, and digital-forward media.